BioMarin Voxzogo Phase 3 Success Triggers Label Expansion **FACT BLOCK:** BioMarin's Voxzogo met primary endpoint. Phase 3 trial for hypochondroplasia succeeded. Company plans label expansion filing. New market segment opens for drug. BioMarin announced positive Phase 3 results for Voxzogo in hypochondroplasia (HCH). The trial met its primary endpoint, demonstrating significant improvement in annualized growth velocity. This success exceeded internal expectations for the rare genetic disorder. Voxzogo, currently approved for achondroplasia, targets the same FGFR3 pathway. This outcome paves the way for a crucial label expansion. This positive data will support a Supplemental New Drug Application (sNDA) with the FDA and a Type II variation with the EMA. BioMarin will leverage existing regulatory pathways for orphan drugs. The FDA's 21 CFR Part 314 governs sNDA submissions. EMA's centralized procedure will facilitate a swift review. Expect filings within the next 12 months, potentially by Q2 2027. The HCH indication expands Voxzogo's market. This move strengthens BioMarin's rare disease portfolio. Competitors like Ascendis Pharma and Pfizer, also developing growth-disorder treatments, face increased pressure. Voxzogo's established safety profile offers a competitive edge. BioMarin aims for market entry into HCH by late 2027.